This Article Abstract Full Text (PDF) All Versions of this Article: 108/20/2467    most recent 01.CIR.0000097122.19430.48v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossi, G. P. Articles by Pessina, A. C. Search for Related Content PubMed PubMed Citation Articles by Rossi, G. P. Articles by Pessina, A. C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Coronary Artery Disease Related Collections Risk Factors Acute coronary syndromes Chronic ischemic heart disease

(Circulation. 2003;108:2467.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Antibodies to Oxidized Low-Density Lipoproteins and Angiographically Assessed Coronary Artery Disease in White Patients

Gian Paolo Rossi, MD; Maurizio Cesari, MD; Renzo De Toni, DBSc; Mario Zanchetta, MD; Giuseppe Maiolino, MD; Luigi Pedon, MD; Chiara Ganzaroli, MD; Pietro Maiolino, MD; Achille C. Pessina, MD, PhD

From the Division of Cardiology, Cittadella Hospital (M.Z., L.P., P.M.), and Department of Clinical and Experimental Medicine (G.P.R., M.C., R.D., G.M., C.G., A.C.P.), Clinica Medica 4, University of Padova, Italy.

Correspondence to Prof Gian Paolo Rossi, MD, FACC, FAHA, Department of Clinical and Experimental Medicine, Clinica Medica 4 University Hospital, via Giustiniani, 2, 35126 Padova, Italy. E-mail gianpaolo.rossi{at}unipd.it

Received May 27, 2003; de novo received July 17, 2003; accepted August 20, 2003.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Low-density lipoprotein (LDL) can be oxidatively modified by reactive oxygen species, thus generating oxLDL. The latter induce formation of specific antibodies (oxLDLAb), which are detectable in patients with atherosclerosis, in which they might play a pathogenic or a protective role. Thus, we aimed to investigate the association of antibodies with oxidized LDLs (oxLDL) (oxLDLAbs) with coronary artery disease (CAD) and acute coronary syndromes.

Methods and Results— In a cross-sectional study of 529 consecutive patients undergoing quantitative coronary angiography for suspected CAD, we measured the titer of IgG oxLDLAbs by ELISA. With regression analysis techniques, we also investigated the determinants of oxLDLAb titer and the association of oxLDLAbs with CAD severity. We found no significant differences of oxLDLAb titer between groups of patients without and with different CAD severity. The oxLDLAb titer was 18.6 enzyme units (EU) (11.5 to 25.7 EU/mL) (mean, 95% CI) in patients without CAD; 16.8 EU (9.6 to 24.2 EU) in patients with stenosis <50%; and 19.9 EU (15 to 24.8 EU), 17.2 (13.8 to 20.6 EU), and 14.7 EU (12.1 to 17.3 EU) in those with in 1-, 2-, or 3-vessel 50% stenosis, respectively. Similarly, no differences of oxLDLAb titer between patients without and with acute coronary syndrome were found. The oxLDLAb titer correlated weakly with aging and with serum total, LDL, and HDL cholesterol and plasma homocysteine levels; however, only age and HDL cholesterol remained significant predictors of the oxLDLAb titer at a stepwise regression analysis.

Conclusions— The results of this study, which was adequately powered from the statistical standpoint, provided no evidence for an association of IgG oxLDLAb titer with angiographically assessed CAD in whites.

Key Words: coronary disease • lipoproteins • antibodies • atherosclerosis • risk factors

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Low-density lipoprotein (LDL) and oxidized LDL (oxLDL) are deemed to play an important role in atherogenesis (for review, see Steinberg et al¹ and Hamilton²). When exposed to reactive oxygen species, LDLs undergo oxidation, a complex process that leads to formation of oxLDL and a number of products derived from lipids through peroxidation and fragmentation. Several lines of evidence support the view that oxLDLs are implicated in atherogenesis (for review, see Steinerova et al,³ Horkko et al,⁴ and Shoenfeld et al⁵). Oxidative modification of LDL can be a prerequisite for rapid accumulation of LDL in macrophages and foam cell formation, and in vitro, oxLDLs were found to resemble biochemically and immunologically the LDL extracted from atherosclerotic lesions.⁶ Accordingly, oxLDLs are deemed to play a key role in the development of atherosclerosis.⁷ Oxidative modification of LDL induces immunogenic epitopes in the LDL molecule,⁸ thus leading to formation of antibodies against oxLDL (oxLDLAbs) that are detectable in sera in the majority of patients with advanced atherosclerotic lesions⁹ and can be measured as a tool for investigating the mechanisms of atherogenesis.¹⁰ Several studies demonstrated an increased titer of oxLDLAbs in patients with atherosclerotic coronary artery disease (CAD),^9,11–13 acute myocardial infarction (MI),¹⁴ and cerebral or peripheral artery disease.^15,16 In contrast, other studies found no such positive relationship between oxLDLAb titers and cardiovascular (CV) phenotypes.^17,18 Of interest, oxLDLAbs were detected in healthy individuals,¹⁹ and a negative (inverse) association between total serum cholesterol and anti-OxLDLAb titers was reported in the general population.²⁰ However, oxLDLAbs were found to block the uptake of oxLDL by macrophages and localize to atherosclerotic plaques in vivo.²¹ More recently, it was reported that autoantibodies to oxLDL derived from "naive" atherosclerotic mice share complete genetic and structural identity with antibodies that protect against common infectious pathogens, including Streptococcus pneumoniae, and that immunization with this latter pathogen induced high circulating levels of oxLDL-specific IgM.²² These antibodies, which were cross-reactive with pneumococcal determinants, decreased the extent of atherosclerosis and localized to atherosclerotic lesions. Thus, oxLDLAbs have been contended both to play a mechanistic role, either protective or pathogenic, and to entail a marker of widespread atherosclerotic disease. However, despite a good deal of research, their true biological role in humans remains unclear, primarily because of the availability of only small-size studies, which are prone to selection biases and serendipitous findings, and because of the lack adequately powered studies. Accordingly, in the consecutive white patients of the GENICA (Genetic and ENvironmental factors In Coronary Artery disease) study²³ who underwent coronary angiography, we sought to determine whether an association between the oxLDLAbs and the extent and severity of CAD existed.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
The criteria for enrollment of the patients and control subjects in the GENICA study were reported previously.²⁴ In brief, consecutive white patients of both sexes consecutively referred to the Division of Cardiology of the Cittadella General Hospital for coronary angiography for investigation of chest pain and/or suspected CAD were enrolled. The only exclusion criterion was the refusal to participate in this study. The Medical Ethics Committee of our university approved the study protocol, and a written consent, after explanation of the aims and details of the study, was obtained from each participant. Two groups served as control subjects: the first included patients in whom significant (eg, stenosis 50%) CAD was eventually ruled out by coronary angiography; the second comprised 33 consecutive healthy normotensive blood donors enrolled at the local blood bank during the same period. Coronary angiography was not performed to rule out the presence of asymptomatic CAD because it would have been ethically unfeasible in these subjects. However, the following inclusion criteria were used for their enrollment: negative family history of CAD, MI, and stroke; nonsmoking status; and absence of hypercholesterolemia, hypertriglyceridemia, and diabetes mellitus, all defined as specified below. On the basis of data from epidemiological and family studies, a cohort fulfilling these criteria is expected to have a very low prevalence of asymptomatic CAD.

Demographic and Clinical Measurements
The medical history of CV events, smoking habits, presence/absence of hypertension, diabetes, hypercholesterolemia, hypertriglyceridemia, and current medications were carefully ascertained.²³ Body mass index was calculated as weight/height² (kg/m²). Criteria for defining current smokers, nonsmokers, and ex-smokers, diabetes mellitus (type I or II), impaired glucose tolerance, hypercholesterolemia, and hypertriglyceridemia were reported previously.²³ Blood pressure was measured by mercury sphygmomanometer using Korotkoff phase V for diastolic, according to the WHO guidelines. Hypertension was defined as systolic pressure 140 mm Hg and/or diastolic pressure 90 mm Hg or use of any antihypertensive agents. Insulin resistance was also quantified by use of the homeostasis model assessment (HOMA).²⁵

Coronary Angiography
Angiography was performed and evaluated by experienced cardiologists who were blinded to the patient’s oxLDLAb titer. The severity of CAD was determined by the number of significantly stenosed coronary arteries.²⁶ Patients were classified as follows: code 1, normal vessels; code 2, <50% stenosis; and codes 3, 4, and 5, stenosis 50% in 1, 2, or 3 major coronary arteries, respectively.²³

Laboratory Measurements
Each patient was studied between 8:30 and 12:00 AM. Before coronary angiography, blood samples were taken from the femoral artery and were immediately centrifuged at 3000g for 10 minutes. Total cholesterol, HDL cholesterol, triglycerides, glucose, sodium, potassium, BUN, and creatinine levels were measured with conventional methods. IgG autoantibodies against malondialdehyde-modified LDL (-oxLDL) were assayed by ELISA with a commercially available ELISA kit (Anti-oxLDL Antibody ELISA KIT; IMMCO Diagnostic Inc), as described by Craig et al²⁷ and according to manufacturer’s specifications. This kit uses individually poached microplate strips that were coated with native or oxLDL; as a result, the antigen stability was shown to last for at least 4 months. Sera were diluted 1:101, and low- and high-titer samples were included in each assay. Furthermore, a standard curve with samples at known oxLDLAb titer was determined for each assay. In our hands, the intra-assay and interassay coefficients of variation of this method were 9% and 15%, respectively.

Statistical Analysis
One-way ANOVA followed by Bonferroni’s post hoc test was used to compare quantitative variables between CAD patients and control subjects. Serum triglycerides, homocysteine, and oxLDLAbs that showed a nongaussian distribution were examined after log transformation. ² analysis was used to compare the frequencies of the categorical coronary risk factors between the CAD and the control groups. To identify the determinants of oxLDLAb titer, we performed a stepwise regression analysis (PIN=0.05, POUT=0.10). Statistical significance was defined as a value of P<0.05. All analyses were performed with SPSS 11.0 for Windows (SPSS Italy Inc).

	Results

Top Abstract Introduction Methods Results Discussion References

 
Sample Size Determination and Demographic Characteristics
We first measured the titer of IgG oxLDLAbs in a pilot study of patients belonging to the different coronary artery groups. On the basis of these results, we calculated (N-Query version 5.0) that at least 500 patients were needed to provide a statistical power of 99% to detect a difference in means characterized by a variance of means, V=r_i(µ_i-µ)²/(r_i) of 621.4, at the 0.05 level, with a 1-way ANOVA, given the common SD that was observed. Thus, for the present study, we randomly enrolled 529 consecutive patients, of the 1271 originally recruited in the GENICA study, who had complete coronary angiography data. Of them, 16% (n=84) had normal coronary arteries; 8% (n=43) had stenosis <50%; 28% (n=147), 27% (n=145), and 21% (n=110) had significant (50%) stenosis in 1, 2, or 3 major epicardial vessels, respectively. Table 1 depicts their main features. Overall, 20% of all these consecutive patients undergoing coronary angiography had an acute coronary syndrome. The proportion of patients with such complications in 1-, 2-, and 3-vessel CAD patients, along with main clinical features, is shown in Table 2.

View this table: [in this window] [in a new window]   TABLE 1. Demographic and Clinical Features of the Whole Population, Classified According to the Angiographically Assessed Coronary Findings

View this table: [in this window] [in a new window]   TABLE 2. Age and Biochemical Features of the Patients With 1-, 2-, and 3-Vessel CAD Classified by the Presence or Absence of Acute Coronary Syndrome

Antibodies to oxLDL
The titer of oxLDLAbs in the group of healthy subjects was 11.5±0.8 enzyme units (EU)/mL (mean±SEM) (11.5 EU and 5.0 to 26.0 EU, median and range). The distribution of values was found to be skewed (skewness index=1.43±0.41; kurtosis index=3.23±0.80); therefore, the 90th percentile value was used as a cutoff for defining normal and high oxLDLAb titers in our population.

No significant differences of oxLDLAb titer between groups without and with CAD were observed. Figure 1 shows that although serum HDL cholesterol decreased stepwise (P<0.001 by ANOVA) along with increasing severity of CAD, no such relationship of oxLDLAb titer with severity of CAD was found. Furthermore, when patients were classified into those without and those with acute coronary syndromes, no significant differences in the titer of oxLDLAbs between groups emerged (Figure 2). Among patients with acute coronary syndrome, those with unstable angina had significantly (P<0.05) higher HDL cholesterol levels than those with acute MI (46.6±1.7 versus 38.2±2.7 mg/dL); however, no differences of oxLDLAb titer were found (21.5±10.6 versus 44.1±27.3 EU/mL) because of the wide spread of the values. A bivariate correlation analysis (Table 3) showed that the oxLDLAb titer was weakly associated with some CV risk factors, eg, it was directly related to age, total serum cholesterol, LDL cholesterol, and plasma homocysteine levels and inversely related to HDL cholesterol. However, only age and HDL cholesterol remained in a stepwise linear regression model; they collectively explained only a minimal proportion of oxLDLAb titer (adjusted R=0.005, P<0.001).

View larger version (26K): [in this window] [in a new window]   Figure 1. Bar graph depicts values of serum HDL cholesterol (black bars) and titer of antibodies to oxLDL (open bars) in patients of GENICA study classified by coronary artery findings at angiography. One-way ANOVA followed by post hoc Bonferroni’s test showed significant differences of serum HDL cholesterol between different groups: normal coronary artery, and stenosis <50% or 50% in 1, 2, or 3 coronary arteries. At variance, no significant differences in oxLDLAb titer between groups were found (mean±SEM).

View larger version (21K): [in this window] [in a new window]   Figure 2. Bar graph depicts serum titer of antibodies to oxLDL in groups of CAD patients who were divided into those with acute coronary syndromes (black bars) and those with stable CAD (open bars). No significant differences were found between former and latter patients in any groups (mean±SEM).

View this table: [in this window] [in a new window]   TABLE 3. Correlation Matrix Showing the Value of Pearson Correlation Coefficient and Significance (1 Tailed) Between oxLDLAb Titer (Ln) and Other Biochemical Variables

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Atherosclerosis is characterized by vascular inflammation and associated with systemic and local immune responses to oxLDL and other antigens (reviewed by Ross²⁸). To gather insight into the relevance of antibodies to oxLDL, we measured their titer in a relatively large sample of patients who underwent coronary angiography because of suspected CAD. These patients entail a population at high risk, eg, with a 20% or greater risk of CV events in the next 10 years, according to the NCEP criteria,²⁹ as mirrored by the fact that the majority of them had already experienced a major CV event. Stable CAD was detected in most (80%) of these patients, and acute coronary syndromes were diagnosed in 20% of them (Table 3). Despite this atherosclerotic burden, we found no significant differences in oxLDL titer either between groups of patients without and with angiographically assessed CAD or between patients with different severity and extension of CAD (Figure 1). These negative findings differ from previous results. According to Inoue et al,⁹ the oxLDLAb titer was higher in 108 Japanese patients who had angiographically confirmed CAD than in 31 patients who had chest pain but no significant CAD. Because these authors also reported higher oxLDLAb titers in 39 patients with acute MI than in 24 patients with no CAD,¹⁴ they contended that the oxLDLAb titer would be higher in the patients with unstable angina and acute MI than in those with stable effort angina and therefore could allow discrimination between patients with these conditions. However, consistent with our present results, they also found no significant differences between the multivessel and single-vessel CAD groups and the control subjects.⁹ High plasma levels of oxLDLAbs have also been associated with carotid artery plaque instability in another study of Japanese patients,³⁰ but conflicting results on the association with carotid atherosclerosis exist in whites.^15,31 A more recent study, in which the ethnicity of case and control subjects was not specified, showed higher IgG oxLDLAb titer in 8 patients with acute MI, compared with 15 patients with unstable angina, 17 patients with stable CAD, or 8 subjects with normal coronary arteries.³² However, higher IgM oxLDLAb titers and higher IgM LDL immune complexes were observed in the normal subjects than the other groups. No such group differences could be confirmed in our study of white patients (Table 1, Figures 1 and 2).

The reasons for these divergent results are at present unclear, although both ethnicity and selection biases might play an important role. The latter explanation is likely to apply to at least 2 of the aforementioned studies in which the number of cases was small and largely exceeded that of control subjects.^9,14 Equally important, it should be acknowledged that coronary angiography focuses on the arterial lumen, rather than on the arterial wall, whereas it has become widely recognized that plaques prone to rupture ("vulnerable plaques") are not those that that yield a high degree of stenosis, eg, the very advanced, fibrotic, and calcified atherosclerotic lesions.³³ It has been established that lesion growth goes hand in hand with compensatory dilatation of the artery wall and that even relatively large lipid-rich vulnerable lesions that might cause acute events, such as MI and ischemic stroke, often result in only minimal stenosis ("Glagov postulate"). Moreover, oxLDLs are most prominent in early lesions but are a minor component in calcified, fibrous, or complicated plaques. Indeed, oxLDL is a major promoter of macrophage activation and other proinflammatory events thought to weaken the fibrous cap. Accordingly, angiography may not be particularly suitable to detect atherosclerotic lesions rich in oxLDL that modulate antibody responses. These considerations might explain the lack of association of antibody titers to oxLDL with the number of the very advanced lesions causing >50% stenosis in this study. However, it should also be noticed that we could find no significant differences between CAD patients without and with acute coronary syndromes (Figure 2).

Whatever the underlying explanation might be, collectively, our present results conclusively ruled out the contention that IgG oxLDLAbs are associated with angiographically assessed CAD. Furthermore, they also make unlikely the hypothesis that they represent a marker for widespread atherosclerotic disease. Similar conclusions were reached in a 10-year study in Finnish type 2 diabetes mellitus patients in whom neither changes of intimal-medial thicknesses of the common carotid artery and carotid bifurcation nor, more importantly, CV events were found to be predicted by the oxLDLAb titer measured at baseline.¹⁷ Results of a number of studies performed in patients with cardiovascular risk factors are also consistent with this conclusion. The oxLDLAb titer was not raised in patients with heterozygous familial hypercholesterolemia compared with matched control subjects³⁴; it was lower in smokers than in nonsmokers,³⁵ and in patients with borderline arterial hypertension than in matched normotensive control subjects.³¹ Moreover, the oxLDLAb titer did not show any differences between men with established hypertension in the ELSA study and normotensive control subjects, nor did it show any association with carotid atherosclerosis.³⁶

Despite the evidence involving oxLDL in atherosclerosis,^1,6 the mechanisms associated with formation of antibodies to oxLDL have not been widely investigated. Thus, to gain some further insight, we sought the determinants of oxLDLAb titer. We found, with a correlation analysis, that only age, total and LDL cholesterol, HDL cholesterol, and plasma homocysteine levels showed statistically significant, albeit very weak, correlations with oxLDLAb titer. Only age and HDL cholesterol remained in a stepwise regression model, thus being identified as significant predictors of oxLDLAb titer; however, the proportion of oxLDL titer variance that was accounted for by these 2 variables was negligible, eg, 5%. Therefore, although oxLDLAb titer appears to increase with aging and to decrease with increasing HDL cholesterol levels, its association with these covariates does not seem to be a strong one.

The present finding of oxLDL in patients without CAD and in normal healthy subjects, which accords with previous reports,^19,20,32 deserves some comment. A complete identity of oxLDLAbs and antibodies from the classic anti-phosphorylcholine B-cell clone T15, which protect against common infectious pathogens, has been unexpectedly found.²² The molecular mimicry between the phosphorylcholine moieties of microbial cell wall polysaccharide and oxLDL was suggested to explain this observation²² and could also account for the previous and present findings of oxLDLAbs in healthy individuals and of increased titer with aging.

Negative findings of a study, like the present ones, should always raise the possibility of inadequate statistical power. In this regard, we would like to point out that (1) our study was the largest ever performed to investigate the biological role of antibodies to oxLDL in patients with angiographically assessed CAD, to the best of our knowledge^{9,11–14,32,35}; and (2) given its total sample size, it had 99% power to detect, with a 1-way ANOVA, an effect size (eg, the variance of the mean divided by the within-group variance) of 0.61, on the basis of the assumptions made earlier.

The lack of association of oxLDLAb titer with CAD could be accounted for by several considerations. First, the assay used in this study measures total IgG antibodies to oxLDL, whereas the antibodies to oxLDL are highly heterogeneous antibodies that differ not only for Ig class but also for epitope specificity and affinity.³⁵ Therefore, it might be that only some of them play a mechanistic role, as suggested by at least 3 lines of evidence. First, IgG and IgM antibodies, as well as immune complexes containing these 2 classes of antibodies, do not follow a similar profile in CAD patients,³² and recent evidence suggests that the protective effect from atherosclerosis can be provided primarily by IgM antibodies.²² Second, a human-derived monoclonal antibody to oxLDL was shown to localize to atherosclerotic lesions in vivo and to block the uptake of oxLDL by macrophages, thus suggesting its potential role in preventing foam cell formation.^21,37 Third, it might also be that only oxLDLAbs directed against some oxidized-phospholipid epitopes and not against others play a major protective role. This contention is supported by a recent study in which oxLDLAbs directed to phosphorylcholine, eg, a key epitope in the protective immune response, proved to be more potent from the standpoint of protection from atherosclerosis than those to malondialdehyde, which were measured in this study.²²

As mentioned, this cross-sectional study comprised exclusively white individuals, and therefore, our findings might not apply to other ethnic groups. Furthermore, although we could not confirm the usefulness of the titer of antibodies to oxLDL as predictor of CAD either in men or in women, we cannot exclude the possibility that this study was underpowered to detect such an association in women, who composed only a minority of our patients.

In conclusion, our results showed no significant association of titer of IgG antibodies to oxLDLAbs and angiographically assessed CAD and acute coronary syndromes. Therefore, they provide no support for the contention of IgG oxLDLAbs to malondialdehyde playing a mechanistic role.

	Acknowledgments

 
This study was supported by grants from the Italian Cabinet of University and Scientific Research (MURST) to Prof A.C. Pessina (9906193152_001/06) and by a research grant from Regione Veneto (863/01/98) and by Unindustria Treviso to Prof G.P. Rossi.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989; 320: 915–924.[Medline] [Order article via Infotrieve]
   
2. Hamilton CA. Low-density lipoprotein and oxidised low-density lipoprotein: their role in the development of atherosclerosis. Pharmacol Ther. 1997; 74: 55–72.[CrossRef][Medline] [Order article via Infotrieve]
   
3. Steinerova A, Racek J, Stozicky F, et al. Antibodies against oxidized LDL: theory and clinical use. Physiol Res. 2001; 50: 131–141.[Medline] [Order article via Infotrieve]
   
4. Horkko S, Binder CJ, Shaw PX, et al. Immunological responses to oxidized LDL. Free Radic Biol Med. 2000; 28: 1771–1779.[CrossRef][Medline] [Order article via Infotrieve]
   
5. Shoenfeld Y, Sherer Y, George J, et al. Autoantibodies associated with atherosclerosis. Ann Med. 2000; 32 (suppl 1): 37–40.[Medline] [Order article via Infotrieve]
   
6. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989; 84: 1086–1095.[Medline] [Order article via Infotrieve]
   
7. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991; 88: 1785–1792.[Medline] [Order article via Infotrieve]
   
8. Erkkila AT, Narvanen O, Lehto S, et al. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000; 20: 204–209.[Abstract/Free Full Text]
   
9. Inoue T, Uchida T, Kamishirado H, et al. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol. 2001; 37: 775–779.[Abstract/Free Full Text]
   
10. Hammer A, Kager G, Dohr G, et al. Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins. Arterioscler Thromb Vasc Biol. 1995; 15: 704–713.[Abstract/Free Full Text]
    
11. Puurunen M, Manttari M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994; 154: 2605–2609.[Abstract]
    
12. Maggi E, Finardi G, Poli M, et al. Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis. 1993; 4: 1119–1122.[Medline] [Order article via Infotrieve]
    
13. Lehtimaki T, Lehtinen S, Solakivi T, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999; 19: 23–27.[Abstract/Free Full Text]
    
14. Inoue T, Yaguchi I, Uchida T, et al. Clinical significance of the antibody against oxidized low-density lipoprotein in acute myocardial infarction. Cardiology. 2002; 98: 13–17.[Medline] [Order article via Infotrieve]
    
15. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992; 339: 883–887.[CrossRef][Medline] [Order article via Infotrieve]
    
16. Bergmark C, Wu R, de Faire U, et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 1995; 15: 441–445.[Abstract/Free Full Text]
    
17. Uusitupa MIJ, Niskanen L, Luoma J, et al. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996; 16: 1236–1242.[Abstract/Free Full Text]
    
18. Schumacher M, Eber B, Tatzber F, et al. Transient reduction of autoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic Biol Med. 1995; 18: 1087–1091.[CrossRef][Medline] [Order article via Infotrieve]
    
19. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med. 2002; 252: 440–447.[CrossRef][Medline] [Order article via Infotrieve]
    
20. Tinahones FJ, Gomez-Zumaquero JM, Rojo-Martinez G, et al. Increased levels of anti-oxidized low-density lipoprotein antibodies are associated with reduced levels of cholesterol in the general population. Metabolism. 2002; 51: 429–431.[CrossRef][Medline] [Order article via Infotrieve]
    
21. Shaw PX, Horkko S, Tsimikas S, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol. 2001; 21: 1333–1339.[Abstract/Free Full Text]
    
22. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003; 9: 736–743.[CrossRef][Medline] [Order article via Infotrieve]
    
23. Rossi GP, Cesari M, Zanchetta M, et al. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol. 2003; 41: 930–937.[Abstract/Free Full Text]
    
24. Pessina AC, Cesari M, Colonna S, et al. Rationale and design of the "GENICA" study (Genetic and Environmental factors In Coronary Atherosclerosis): a study of the genetic factors playing a role in the development of coronary atherosclerosis. High Blood Press Cardiovasc Prev. 2001; 9: 83–85.
    
25. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412–419.[CrossRef][Medline] [Order article via Infotrieve]
    
26. Wang XL, Sim AS, Badenhop RF, et al. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med. 1996; 2: 41–45.[CrossRef][Medline] [Order article via Infotrieve]
    
27. Craig WY, Poulin SE, Nelson CP, et al. ELISA of IgG antibody to oxidized low density lipoprotein: effects of blocking buffer and method of data expression. Clin Chem. 1994; 40: 882–888.[Abstract/Free Full Text]
    
28. Ross R. Atherosclerosis: an inflammatory disease. Nature. 1999; 340: 115–126.
    
29. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.[Free Full Text]
    
30. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002; 22: 1649–1654.[Abstract/Free Full Text]
    
31. Wu R, de Faire U, Lemne C, et al. Autoantibodies to oxLDL are decreased in individuals with borderline hypertension. Hypertension. 1999; 33: 53–59.[Abstract/Free Full Text]
    
32. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003; 41: 360–370.[Abstract/Free Full Text]
    
33. Ambrose JA, Fuster V. Can we predict future acute coronary events in patients with stable coronary artery disease? JAMA. 1997; 277: 343–344.[CrossRef][Medline] [Order article via Infotrieve]
    
34. Hulthe J, Wikstrand J, Lidell A, et al. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1998; 18: 1203–1211.[Abstract/Free Full Text]
    
35. Zaratin A, Gidlund M, Boschcov P, et al. Antibodies against oxidized low-density lipoprotein in normolipidemic smokers. Am J Cardiol. 2002; 90: 651–653.[CrossRef][Medline] [Order article via Infotrieve]
    
36. Frostegard J, Wu R, Lemne C, et al. Circulating oxidized low density lipoprotein is increased in hypertension. Clin Sci (Lond). July 1, 2003. 10.1042/CS20030152. Available at: http://www.clinsci.org. Accessed October 20, 2003.
    
37. Horkko S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999; 103: 117–128.[Medline] [Order article via Infotrieve]
    

This article has been cited by other articles:

				S. Tsimikas, E. S. Brilakis, R. J. Lennon, E. R. Miller, J. L. Witztum, J. P. McConnell, K. S. Kornman, and P. B. Berger Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events J. Lipid Res., February 1, 2007; 48(2): 425 - 433. [Abstract] [Full Text] [PDF]

				G. P. Rossi, G. Maiolino, M. Zanchetta, D. Sticchi, L. Pedon, M. Cesari, D. Montemurro, R. De Toni, S. Zavattiero, and A. C. Pessina The T-786C Endothelial Nitric Oxide Synthase Genotype Predicts Cardiovascular Mortality in High-Risk Patients J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1166 - 1174. [Abstract] [Full Text] [PDF]

				M. Mayr, S. Kiechl, S. Tsimikas, E. Miller, J. Sheldon, J. Willeit, J. L. Witztum, and Q. Xu Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2436 - 2443. [Abstract] [Full Text] [PDF]

				J. Durga, L. J. H. van Tits, E. G. Schouten, F. J. Kok, and P. Verhoef Effect of Lowering of Homocysteine Levels on Inflammatory Markers: A Randomized Controlled Trial Arch Intern Med, June 27, 2005; 165(12): 1388 - 1394. [Abstract] [Full Text] [PDF]

				I. Goncalves, M.-L. M. Gronholdt, I. Soderberg, M. P.S. Ares, B. G. Nordestgaard, J. F. Bentzon, G. N. Fredrikson, and J. Nilsson Humoral Immune Response Against Defined Oxidized Low-Density Lipoprotein Antigens Reflects Structure and Disease Activity of Carotid Plaques Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1250 - 1255. [Abstract] [Full Text] [PDF]

				F. J. Tinahones, J. M. Gomez-Zumaquero, L. Garrido-Sanchez, E. Garcia-Fuentes, G. Rojo-Martinez, I. Esteva, M. S. R. de Adana, F. Cardona, and F. Soriguer Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population J. Lipid Res., March 1, 2005; 46(3): 452 - 457. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 108/20/2467    most recent 01.CIR.0000097122.19430.48v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossi, G. P. Articles by Pessina, A. C. Search for Related Content PubMed PubMed Citation Articles by Rossi, G. P. Articles by Pessina, A. C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Coronary Artery Disease Related Collections Risk Factors Acute coronary syndromes Chronic ischemic heart disease